Paper Details

  1. Home
  2. Paper Details

Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.

Author: LinMao-Fang, OuyangGui-Fang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Bortezomib (Bor) combined with daunorubicin (DNR) showed a synergistic inhibitory effect on human multiple myeloma cell line KM3 in vitro, indicating a potential for combined therapy.
Paper Details　
Original Abstract of the Article :
The aim of this study was to investigate the combined effects of bortezomib (Bor) and daunorubicin (DNR) or each drug alone on proliferation of human multiple myeloma cell line KM3. KM3 cells were cultured with different concentrations of Bor and DNR, Bor or DNR alone for different times. The cell p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20030928

データ提供：米国国立医学図書館（NLM）

Combating Multiple Myeloma with a Two-Pronged Approach

Multiple myeloma is a complex cancer, like a shifting sand dune, that can be difficult to treat. This study investigates the combined effects of bortezomib and daunorubicin, two anti-cancer drugs, on human multiple myeloma cells. The study aims to determine if the combination of these drugs has a synergistic effect, potentially leading to more effective treatment outcomes.

A Powerful Combination Against Cancer

This study demonstrates the synergistic effect of combining bortezomib and daunorubicin for the treatment of multiple myeloma. The study's findings suggest that this combination therapy could be more effective than using either drug alone, potentially leading to improved treatment outcomes for patients with this challenging cancer.

New Hope for Multiple Myeloma Treatment

This research offers a promising avenue for treating multiple myeloma, a complex cancer with limited treatment options. The study's findings highlight the potential for combining bortezomib and daunorubicin to enhance treatment efficacy, potentially offering a more effective and durable treatment for patients with this debilitating disease.

Dr.Camel's Conclusion

This study delves into the complex world of multiple myeloma, exploring the potential for a two-pronged approach using bortezomib and daunorubicin. The study's findings offer hope for more effective treatment strategies for this challenging cancer, potentially leading to improved outcomes for patients.
Date :
  1. Date Completed 2011-08-23
  2. Date Revised 2016-10-18
Further Info :

Pubmed ID

20030928

DOI: Digital Object Identifier

1009-2137(2009)06-1468-04

Related Literature

Article Analysis
・Effects of daunorubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.